The consensus price target hints at a 32.6% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in upcoming investor conferences.
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced the publication of a new article demonstrating the company's leadership in applying AI to accelerate and enhance genetic diagnostics.
GeneDx delivered strong Q1 2025 results, beating revenue and EPS estimates, and raised full-year guidance despite a minor sequential test volume dip. The volume decline is attributable to seasonality,

GeneDx: Time To Buy The Dip

05:35am, Wednesday, 14'th May 2025
GeneDx's recent 50% stock drop post-Q1 earnings is seen as an overreaction, despite a projected modest growth slowdown from 42% to 30-35%. The company is expanding product lines, improving margins, an
GAITHERSBURG, Md. & OAKLAND, Calif.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced the successful completion of its acquisition of Fabric Genomics, a pioneer in AI-powered genomic interpretati

Best Momentum Stocks to Buy for May 5th

11:01am, Monday, 05'th May 2025
WGS, EBMT and CBNK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 5, 2025.

New Strong Buy Stocks for May 5th

09:20am, Monday, 05'th May 2025
WGS, NWG, HLF, CALM and ESEA have been added to the Zacks Rank #1 (Strong Buy) List on May 5, 2025.
With a nearly 39% stock price decline this week, according to data compiled by S&P Global Market Intelligence, GeneDx Holdings (WGS 7.80%) was deep in the doghouse with investors. They traded out of t
GeneDx Holdings Corp. (NASDAQ:WGS ) Q1 2025 Earnings Conference Call April 30, 2025 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - Chief Executive Officer Kev

Why GeneDx Holdings Stock Is Plunging Today

12:28pm, Wednesday, 30'th Apr 2025
Shares of GeneDx Holdings (WGS -39.70%) were plunging 42.9% as of 11:21 a.m. ET on Wednesday.
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.33 per share a year ago.
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the first quarter of 2025.
GENEDX HOLDINGS (WGS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GeneDx Holdings Corp. leverages genomic sequencing and data science for early diagnosis and treatment, focusing on pediatric outpatient and neonatal ICU settings. GeneDx will report Q1 2025 earnings o
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE